FDA Expands Sunscreen Options for the First Time in 20 Years
FDA adds bemotrizinol to permitted sunscreen active ingredients, expanding options for the first time in 20 years.
Aforeworn detected this change in the Cosmetics & Personal-Care (MoCRA) space on July 6, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Cosmetic and personal care businesses, especially sunscreen manufacturers, indie brands, contract manufacturers, private-label makers, and importers/distributors. should confirm how it applies to their specific situation before acting. There is a time constraint attached: No immediate deadline; businesses can adopt at their own pace.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Cosmetics & Personal-Care (MoCRA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Bemotrizinol is now a permitted sunscreen active ingredient in the U.S., allowing new formulations.
Who it affects
Cosmetic and personal care businesses, especially sunscreen manufacturers, indie brands, contract manufacturers, private-label makers, and importers/distributors.
What you must do
Review current sunscreen product formulations and consider reformulating to include bemotrizinol if desired.
Deadline
No immediate deadline; businesses can adopt at their own pace.
Source: http://www.fda.gov/news-events/press-announcements/fda-expands-sunscreen-options-first-time-20-years
Never miss a change like this again
Aforeworn watches Cosmetics & Personal-Care (MoCRA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Cosmetics & Personal-Care (MoCRA)
- FDA Launches One-Day Inspectional Assessments to Strengthen and Expand Oversight
- FDA Grants Seventh Approval under the National Priority Voucher Pilot Program
- FDA Issues Guidance to Improve Collection of Pregnancy Safety Data for Drugs and Biologics
- FDA Expands AI Capabilities and Completes Data Platform Consolidation
- FDA Approves First Treatment for Chronic Hepatitis Delta Virus (HDV) Infection